Stanley-Laman Group’s Neurocrine Biosciences NBIX Stock Holding History

Stanley-Laman Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.63M	Sell	27,446 -103	-0.4%	-$15.3K	0.47%	64
2026 Q1	$3.63M	Sell	27,549 -69	-0.2%	-$9.15K	0.45%	91
2025 Q4	$3.92M	Buy	27,618 +2,264	+9%	+$328K	0.5%	78
2025 Q3	$3.56M	Sell	25,354 -17,167	-40%	-$2.33M	0.51%	81
2025 Q2	$5.34M	Buy	42,521 +9,862	+30%	+$1.13M	0.79%	34
2025 Q1	$3.61M	Sell	32,659 -9,499	-23%	-$1.2M	0.56%	77
2024 Q4	$5.75M	Buy	42,158 +4,627	+12%	+$572K	0.81%	26
2024 Q3	$4.32M	Buy	37,531 +10,088	+37%	+$1.38M	0.61%	63
2024 Q2	$3.78M	Buy	+27,443	New	+$3.76M	0.54%	82
2018 Q3	–	Sell	-89,884	Closed	-$8.83M	–	233
2018 Q2	$8.83M	Buy	89,884 +10,728	+14%	+$960K	1.98%	3
2018 Q1	$6.56M	Sell	79,156 -9,990	-11%	-$844K	1.5%	7
2017 Q4	$6.92M	Buy	89,146 +33,723	+61%	+$2.3M	1.49%	6
2017 Q3	$3.4M	Buy	+55,423	New	+$2.92M	0.91%	36

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Stanley-Laman Group's NBIX Position: Q2 2026 in Review

Stanley-Laman Group reduced its Neurocrine Biosciences (NBIX) stake by 0.37% in Q2 2026, selling an estimated $15.3K and leaving 27,446 shares worth $4.63M. The position accounts for 0.47% of the portfolio, ranked #64.

Stanley-Laman Group first reported a position in NBIX in Q3 2017 and has held it in 13 quarters since. The position peaked at $8.83M in Q2 2018. 776 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Stanley-Laman Group held 27,446 shares of Neurocrine Biosciences worth $4.63M as of Q2 2026.
Stanley-Laman Group sold 103 Neurocrine Biosciences shares in Q2 2026, an estimated $15.3K.
Neurocrine Biosciences made up 0.47% of Stanley-Laman Group's portfolio in Q2 2026, its #64 holding.
Stanley-Laman Group first reported a position in Neurocrine Biosciences in Q3 2017 and has held it in 13 quarters since.
Stanley-Laman Group's Neurocrine Biosciences position peaked at $8.83M in Q2 2018.
776 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Stanley-Laman Group's 13F filing for Q2 2026, filed 5 Aug 2026.